La afectación neurológica en la enfermedad de Gaucher

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Fundación Española para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG) Sanofi-Genzyme; Giraldo Castellano, Pilar Camacho Molina, Alejandra Capablo Liesa, José Luis.
Recurso de Internet en Español | LIS - Localizador de Información en Salud, LIS-ES-PROF | ID: lis-42016

Documentos relacionados

  1. Direct activation of microglia by ß-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease.
  2. Photoredox-based late-stage functionalization in SAR study for in vivo potent glucosylceramide synthase inhibitor.
  3. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.
  4. Animal Models for the Study of Gaucher Disease.
  5. The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO).
  6. Gaucher's Disease.
  7. Long-term follow-up of a patient with neonatal form of Gaucher disease.
  8. [Gaucher disease: achievements and prospects].
  9. Diagnosis, treatment and genetic analysis of an elderly patient with Gaucher's disease characterized by marked multiple bone destruction.
  10. Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report.